Tai Yulei, Zhang Meng, Han Yuning, Hu Hui, Lin Shan, Zhai Fangya, Tian Menglun, Song Xiaojun, Wan Shuangshuang, Chen Yu, Jin Dazhi
School of Laboratory of Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Hangzhou, Zhejiang, China.
Front Microbiol. 2025 Jul 30;16:1617631. doi: 10.3389/fmicb.2025.1617631. eCollection 2025.
INTRODUCTION: Niclosamide (NIC) has significant potential as a clinical therapeutic agent for infection (CDI); however, its strong hydrophobicity hampers its oral bioavailability, and its active effects against remain unclear. METHODS: Niclosamide-loaded controlled-release hyaluronic acid-modified poly (lactic--glycolic acid) naosphernes (NIC@PLGA-HAs) were synthesized using an oil-in-water emulsion technique and their effects on cell growth, spore germination, biofilm formation, and NIC interaction sites with toxin B (TcdB) were analyzed. RESULTS: NIC@PLGA-HAs exhibited enhanced solubility and stability, with a water contact angle on a hydrophilic surface of 65.1° and a zeta potential of 31.57 ± 2.08 mV, and pH-responsive (pH 7.4) controlled-release characteristics compared to free NIC. The NIC@PLGA-HAs killed vegetative cells at a minimum inhibitory concentration (MIC) of 4 μg/mL. When cells were treated with NIC@PLGA-HAs at the 1/4 MIC, spore germination and biofilm formation were significantly inhibited compared to those in untreated cells ( < 0.01). NIC was found to interact with the receptor-binding domain of TcdB at 24 amino acid sites via an enthalpy-driven reaction (enthalpy change, 36.21 kJ/mol and entropy change, 212.9 J⋅mol/K). experimental findings in Mongolian gerbils indicated that NIC@PLGA-HAs outperformed free NIC in reducing pathological damage, diarrhea severity, weight loss, and TcdB production and enhanced the survival rate. CONCLUSION: These findings presented the therapeutic potential of NIC@PLGA-HAs with high solubility and stability, which simultaneously exerted multiple biological activities against .
引言:硝唑尼特(NIC)作为艰难梭菌感染(CDI)的临床治疗药物具有巨大潜力;然而,其强疏水性阻碍了口服生物利用度,且其对艰难梭菌的活性作用仍不清楚。 方法:采用水包油乳液技术合成了载硝唑尼特的控释透明质酸修饰聚(乳酸-乙醇酸)纳米球(NIC@PLGA-HAs),并分析了其对艰难梭菌细胞生长、孢子萌发、生物膜形成以及NIC与毒素B(TcdB)相互作用位点的影响。 结果:与游离NIC相比,NIC@PLGA-HAs表现出增强的溶解性和稳定性,在亲水性表面的水接触角为65.1°,zeta电位为31.57±2.08 mV,具有pH响应性(pH 7.4)控释特性。NIC@PLGA-HAs在最低抑菌浓度(MIC)为4μg/mL时可杀死艰难梭菌营养细胞。当用1/4 MIC的NIC@PLGA-HAs处理艰难梭菌细胞时,与未处理细胞相比,孢子萌发和生物膜形成受到显著抑制(P<0.01)。发现NIC通过焓驱动反应在24个氨基酸位点与TcdB的受体结合域相互作用(焓变,36.21 kJ/mol;熵变,212.9 J·mol/K)。在蒙古沙鼠中的实验结果表明,NIC@PLGA-HAs在减轻病理损伤、腹泻严重程度、体重减轻和TcdB产生方面优于游离NIC,并提高了存活率。 结论:这些发现揭示了具有高溶解性和稳定性的NIC@PLGA-HAs的治疗潜力,其同时对艰难梭菌发挥多种生物学活性。
Therap Adv Gastroenterol. 2025-6-21
Cochrane Database Syst Rev. 2017-12-19
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2023-4-25
Cochrane Database Syst Rev. 2005-1-25
Cochrane Database Syst Rev. 2011-9-7
Cochrane Database Syst Rev. 2017-3-3
Lancet Reg Health Am. 2024-8-30
Int J Mol Sci. 2024-5-29
Front Microbiol. 2024-4-4